{"entity":{"id":"nct06951399","kind":"trial","name":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of pembrolizumab in lung cancer, run by Rabin Medical Center, not yet recruiting.","summary":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT06951399 by Rabin Medical Center, with a registry enrolment figure of 30 participants, started 2025-09-01 and due to reach its primary completion in 2027-08-30. Interventions recorded: Pembrolizumab (KEYTRUDA®). Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC Stage IV Without EGFR/ALK Mutation; NSCLC Adenocarcinoma. Primary outcome: Change in T-cell Receptor (TCR) Repertoire Clonality and Diversity Relative to Disease Response Assessed by RECIST v1.1. Lung eligibility wording from the registry: \"* Histologically confirmed diagnosis of NSCLC adenocarcinoma stage IV or unresectable stage III\". Sites: Israel. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06951399","url":"https://clinicaltrials.gov/study/NCT06951399"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","alk-positive-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06951399","phase":"2","setting":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-Small Lung Cancer","sponsor":"Rabin Medical Center","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06951399/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}